Skip to main content Accessibility help
×
Home
Hostname: page-component-846f6c7c4f-9v9hh Total loading time: 0.265 Render date: 2022-07-07T15:19:20.541Z Has data issue: true Feature Flags: { "shouldUseShareProductTool": true, "shouldUseHypothesis": true, "isUnsiloEnabled": true, "useRatesEcommerce": false, "useNewApi": true } hasContentIssue true

Duloxetine for the Treatment of Generalized Social Anxiety Disorder: A Preliminary Randomized Trial of Increased Dose to Optimize Response

Published online by Cambridge University Press:  07 November 2014

Abstract

Objective: This is the first trial examining duloxetine for generalized social anxiety disorder (GSAD) and the effect of increased dose for those without early remission.

Methods: Individuals (n=39) with GSAD received 6 weeks of open-label duloxetine 60 mg/day; those with a Liebowitz Social Anxiety Disorder Scale (LSAS) score >30 at week 6 were randomized in double-blind fashion to an additional 18 weeks of continued duloxetine 60 mg/day or to duloxetine 120 mg/day.

Results: Duloxetine was associated with a significant LSAS reduction at week 6 (91.3 [17.7] to 69.8 [28.5], paired t [df]=5.2 [38], P<.0001), and randomized participants overall continued to improve at week 24 (74.6 [23.9] to 60.3 [29.7]; paired t [df]=3.3 [27], P=.0026). Though the increased dose strategy was associated with a moderate effect size (Cohen's d=.57), there was no significant difference at week 24 endpoint in LSAS reduction (20.5 [26.0] versus 7.3 [17.2], t [df]=1.6 [26], P=.13) nor remission (33% versus 8%) for duloxetine with dose increased to 120 mg/day compared to duloxetine continued at 60 mg/day. Overall, 44% (17/39) discontinued prior to week 24.

Conclusions: Though with limited power, these data provide preliminary support for the efficacy of duloxetine for GSAD, and suggest continued improvement but limited remission overall at 24 weeks for individuals remaining symptomatic at week 6. These observations warrant further controlled study.

Type
Original Research
Copyright
Copyright © Cambridge University Press 2010

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Kessler, RC, Berglund, P, Demler, O, Jin, R, Merikangas, KR, Walters, EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005; 62(6): 593602.CrossRefGoogle ScholarPubMed
2.Van Ameringen, MA, Lane, RM, Walker, JR, et al. Sertraline treatment of generalized social phobia: a 20-week, double-blind, placebo-controlled study. Am J Psychiatry. 2001; 158(2): 275281.CrossRefGoogle ScholarPubMed
3.Stein, MB, Liebowitz, MR, Lydiard, RB, Pitts, CD, Bushnell, W, Gergel, I. Paroxetine treatment of generalized social phobia (social anxiety disorder): a randomized controlled trial. JAMA. 1998; 280(8): 708713.CrossRefGoogle ScholarPubMed
4.Stein, MB, al. e. Efficacy of low and higher dose extended-release venlafaxine in generalized social anxiety disorder: a 6-month randomized controlled trial. Psychopharmacology. 2005; 177(3): 280288.CrossRefGoogle ScholarPubMed
5.Stein, MB, Pollack, MH, Bystritsky, A, Kelsey, JE, Mangano, RM. Efficacy of low and higher dose extended-release venlafaxine in generalized social anxiety disorder: a 6-month randomized controlled trial. Psychopharmacology. 2005; 177(3): 280288.CrossRefGoogle ScholarPubMed
6.Liebowitz, MR, Stein, MB, Tancer, M, Carpenter, D, Oakes, R, Pitts, CD. A randomized, double-blind, fixed-dose comparison of paroxetine and placebo in the treatment of generalized social anxiety disorder. J Clin Psychiatry. 2002; 63(1): 6674.CrossRefGoogle ScholarPubMed
7.Dunner, DL, Goldstein, DJ, Mallinckrodt, C, Lu, Y, Detke, MJ. Duloxetine in treatment of anxiety symptoms associated with depression. Depress Anxiety. 2003; 18(2): 5361.CrossRefGoogle ScholarPubMed
8.Fava, M, Martinez, JM, Greist, J, et al. The efficacy and tolerability of duloxetine in the treatment of anxious versus non-anxious depression: a post-hoc analysis of an open-label outpatient study. Ann Clin Psychiatry. 2007; 19(3): 187195.CrossRefGoogle ScholarPubMed
9.Koponen, H, Allgulander, C, Erickson, J, et al. Efficacy of duloxetine for the treatment of generalized anxiety disorder: implications for primary care physicians. Prim Care Companion J Clin Psychiatry. 2007; 9(2): 100107.CrossRefGoogle ScholarPubMed
10.Crippa, JA, Filho, AS, Freitas, MC, Zuardi, AW. Duloxetine in the treatment of social anxiety disorder. J Clin Psychopharmacol. 2007; 27(3): 310.CrossRefGoogle ScholarPubMed
11.Lin, CC. Duloxetine treatment of social anxiety disorder with comorbid major depression. J Clin Psychopharmacol. 2008; 28(5): 591592; author reply 592–593.CrossRefGoogle ScholarPubMed
12.Scott, EL, Pollack, MH, Otto, MW, Simon, NM, Worthington, JJ. Clinician response to treatment refractory panic disorder: a survey of psychiatrists. J Nerv Ment Dis. 1999; 187(12): 755757.CrossRefGoogle ScholarPubMed
13.First, MS, Gibbon, M, Williams, JBW. Structured Clinical Interview for Axis I DSM-IV Disorders - Patient version (SCID-1/P version 2.0). New York, NY: New York State Psychiatric Institute Biometrics Research Department; 1994.Google Scholar
14.Doyle, AC, Pollack, MH. Establishment of remission criteria for anxiety disorders. J Clin Psychiatry. 2003; 64(Suppl 15): 4045.Google ScholarPubMed
15.Ballenger, JC. Clinical guidelines for establishing remission in patients with depression and anxiety. J Clin Psychiatry. 1999; 60(Suppl 22): 2934.Google ScholarPubMed
16.Sheehan, DV, Harnett-Sheehan, K, Raj, BA. The measurement of disability. Int Clin Psychopharmacol. 1996; 11(Suppl 3): 8995.CrossRefGoogle ScholarPubMed
17.Endicott, J, Nee, J, Harrison, W, Blumenthal, R. Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure. Psychopharmacol Bull. 1993; 29(2): 321326.Google ScholarPubMed
18.Rapaport, MH, Davidson, JR. The efficacy of new pharmacological treatments for panic disorder: evaluating the trials. Psychopharmacol Bull. 1998; 34(2): 167168.Google ScholarPubMed
19.Schneier, FR, Heckelman, LR, Garfinkel, R, et al. Functional impairment in social phobia. J Clin Psychiatry. 1994; 55(8): 322331.Google ScholarPubMed
20.Davidson, JR. Pharmacotherapy of social anxiety disorder: what does the evidence tell us? J Clin Psychiatry. 2006; 67(Suppl 12): 2026.Google ScholarPubMed
21.Kornstein, SG, Dunner, DL, Meyers, AL, et al. A randomized, double-blind study of increasing or maintaining duloxetine dose in patients without remission of major depressive disorder after initial duloxetine therapy. J Clin Psychiatry. 2008; 69(9): 13831392.CrossRefGoogle ScholarPubMed
22.Cymbalta delayed-release capsules. In: Physician's Desk Reference. 63rd ed. Montvale, NJ: Thomson PDR; 2009.Google Scholar
7
Cited by

Save article to Kindle

To save this article to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Duloxetine for the Treatment of Generalized Social Anxiety Disorder: A Preliminary Randomized Trial of Increased Dose to Optimize Response
Available formats
×

Save article to Dropbox

To save this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you used this feature, you will be asked to authorise Cambridge Core to connect with your Dropbox account. Find out more about saving content to Dropbox.

Duloxetine for the Treatment of Generalized Social Anxiety Disorder: A Preliminary Randomized Trial of Increased Dose to Optimize Response
Available formats
×

Save article to Google Drive

To save this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you used this feature, you will be asked to authorise Cambridge Core to connect with your Google Drive account. Find out more about saving content to Google Drive.

Duloxetine for the Treatment of Generalized Social Anxiety Disorder: A Preliminary Randomized Trial of Increased Dose to Optimize Response
Available formats
×
×

Reply to: Submit a response

Please enter your response.

Your details

Please enter a valid email address.

Conflicting interests

Do you have any conflicting interests? *